类风湿性关节炎药物市场规模、份额、成长分析（按分子、销售管道、给药途径和地区）- 产业预测，2025 年至 2032 年

2023 年全球类风湿性关节炎药物市场规模为 258 亿美元，预计将从 2024 年的 273.5 亿美元成长到 2032 年的 435.9 亿美元，预测期内（2025-2032 年）的复合年增长率为 6.0%。

受关节炎和关节併发症盛行率上升的推动，全球类风湿性关节炎药物市场正在经历显着增长。类风湿性关节炎盛行率的增加、相关药物的需求、专利到期以及生物相似药的出现等因素对于此扩张至关重要。人口老化、传统缓解疾病药物（DMARD）使用量的增加以及政府为提高公众意识和鼓励创新治疗研究而采取的积极倡议进一步加强了市场活力。与知名产业参与者的合作以及活性化的医疗改革力度正在推动这些治疗方法的研究和应用。协同效应联合治疗的趋势也越来越受到支持，因为患者可以从多方面的治疗方法中受益匪浅。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管格局
• 案例研究
• 技术分析

类风湿性关节炎药物市场规模（依分子）

• 市场概览
• 製药
  • 非类固醇消炎剂
  • 止痛药
  • 抗风湿药物
  • 糖皮质激素
• 生物製药
  • 生物製药
    • TNF-α拮抗剂
    • T细胞抑制剂
    • CD20抗体
    • JAK抑制剂
    • 抗IL6生物製药
  • 生物相似药
    • CD20抗原
    • TNF-α拮抗剂

类风湿性关节炎治疗市场规模（依销售管道）

• 市场概览
• 处方笺
• 场外交易（OTC）

类风湿性关节炎治疗市场规模（依给药途径）

• 市场概览
• 口服
• 肠外

类风湿性关节炎治疗市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• AbbVie Inc.（USA）
• Pfizer Inc.（USA）
• Amgen Inc.（USA）
• Eli Lilly and Company（USA）
• Bristol-Myers Squibb Company（USA）
• Johnson & Johnson（USA）
• Novartis AG（Switzerland）
• F. Hoffmann-La Roche Ltd（Switzerland）
• UCB SA（Belgium）
• Takeda Pharmaceutical Company Limited（Japan）
• Astellas Pharma Inc.（Japan）
• Eisai Co., Ltd.（Japan）
• Chugai Pharmaceutical Co., Ltd.（Japan）
• Kyowa Kirin Co., Ltd.（Japan）
• Sun Pharmaceutical Industries Ltd.（India）
• Lupin Limited（India）
• Zydus Lifesciences Limited（India）
• Cipla Ltd.（India）
• Dr. Reddy's Laboratories Ltd.（India）

结论和建议

Global Rheumatoid Arthritis Drugs Market size was valued at USD 25.8 billion in 2023 and is poised to grow from USD 27.35 billion in 2024 to USD 43.59 billion by 2032, growing at a CAGR of 6.0% during the forecast period (2025-2032).

The global rheumatoid arthritis drugs market is experiencing significant growth, driven by the rising incidence of arthritis and joint complications. Factors such as the increasing prevalence of rheumatoid arthritis, the demand for related medications, patent expirations, and the emergence of biosimilars are pivotal in this expansion. The ageing population, combined with a greater utilization of conventional Disease-Modifying Anti-Rheumatic Drugs (DMARDs) and proactive government initiatives to enhance public awareness and encourage innovative treatment research, further bolster market dynamics. Collaborations with prominent industry players and increased healthcare reforms are fostering research and adoption of these therapies. The trend towards combination therapies, offering synergistic benefits, is also gaining traction, catering to patients who can significantly benefit from a multifaceted treatment approach.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Rheumatoid Arthritis Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Rheumatoid Arthritis Drugs Market Segments Analysis

Global Rheumatoid Arthritis Drugs Market is segmented by Molecule, Sales Channel, Route of Administration and region. Based on Molecule, the market is segmented into Pharmaceuticals and Biopharmaceuticals. Based on Sales Channel, the market is segmented into Prescription and Over-the-Counter (OTC). Based on Route of Administration, the market is segmented into Oral and Parenteral. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Rheumatoid Arthritis Drugs Market

The growing prevalence of rheumatoid arthritis worldwide serves as a significant driver for the expansion of the global rheumatoid arthritis drugs market. With an aging population and changing dietary habits contributing to the rise in cases of this debilitating condition, there is an increasing demand for effective treatment solutions. This heightened need for innovative and efficient therapies underscores the urgency for advancements in this sector, thereby fostering market growth. As efforts to address the challenges of rheumatoid arthritis continue to evolve, the global market for related pharmaceuticals is poised for significant development in response to these pressing healthcare needs.

Restraints in the Global Rheumatoid Arthritis Drugs Market

Concerns regarding the safety of long-term use of certain rheumatoid arthritis medications, particularly biologics and JAK inhibitors, present a significant challenge to the growth of the market. Both patients and healthcare professionals often hesitate to utilize these therapies due to potential adverse effects, including an increased risk of infections, cardiovascular issues, and cancer. This reluctance impacts the rate at which these treatments are adopted and integrated into clinical practice, ultimately slowing their acceptance and market penetration. As a result, these safety apprehensions create a notable restraint on the overall expansion of the global rheumatoid arthritis drugs market.

Market Trends of the Global Rheumatoid Arthritis Drugs Market

The global rheumatoid arthritis drugs market is experiencing a significant trend towards the adoption of biologic therapies, which encompass advanced treatments such as monoclonal antibodies and Janus kinase (JAK) inhibitors. These innovative drugs are gaining traction due to their targeted mechanisms of action, offering enhanced efficacy and a favorable safety profile compared to traditional therapies. As healthcare providers and patients increasingly recognize the benefits of biologics in managing moderate to severe rheumatoid arthritis, their market penetration continues to rise. This shift towards biologic treatments is poised to reshape the landscape of rheumatoid arthritis therapeutics, driving growth and innovation in the industry.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Analysis

Global Rheumatoid Arthritis Drugs Market Size by Molecule & CAGR (2025-2032)

• Market Overview
• Pharmaceuticals
  • NSAIDs
  • Analgesics
  • DMARDs
  • Glucocorticoids
• Biopharmaceuticals
  • Biologics
    • TNF-a antagonists
    • T-cell inhibitors
    • CD20 antigen
    • JAK inhibitors
    • anti-IL6 biologics
  • Biosimilars
    • CD20 antigen
    • TNF-a antagonists

Global Rheumatoid Arthritis Drugs Market Size by Sales Channel & CAGR (2025-2032)

• Market Overview
• Prescription
• Over-the-Counter (OTC)

Global Rheumatoid Arthritis Drugs Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Parenteral

Global Rheumatoid Arthritis Drugs Market Size & CAGR (2025-2032)

• North America (Molecule, Sales Channel, Route of Administration)
  • US
  • Canada
• Europe (Molecule, Sales Channel, Route of Administration)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Molecule, Sales Channel, Route of Administration)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Molecule, Sales Channel, Route of Administration)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Molecule, Sales Channel, Route of Administration)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB S.A. (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chugai Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kyowa Kirin Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations